The following is a summary of “Comparing the efficacy and complications of Endoscopic Biliary Drainage (EBD) and Percutaneous Transhepatic Biliary Drainage (PTBD) in patients with perihilar cholangiocarcinoma,” published in the December 2022 issue of Primary care by Pirayvatlou, et al.
Patients with biliary illness may develop uncommon cancer hilar cholangiocarcinoma (HCCA). Untreated jaundice and blockage before surgery can result in cholangitis, a delay in tumor therapy, a decline in quality of life, and an increased risk of death. The main form of therapy for HCCA is surgery. For a study, researchers sought to examine the effectiveness and side effects of endoscopic biliary drainage (EBD) with percutaneous transhepatic biliary drainage (PTBD).
The cohort research involved 20 biliary obstruction patients split into two groups, EBD and PTBD, using simple random selection. Patients were compared in terms of bilirubin levels and postoperative sequelae three weeks following surgery. Inferential statistics (independent t-test, Chi-square test, and Fisher’s test) and descriptive statistics (table, mean, and standard deviation) were used to examine the data.
According to an independent t-test, there was no discernible difference between the two groups’ bilirubin levels (P = 0.77). However, independent t-test results revealed that this difference was not significant (P = 0.08), despite a drop in bilirubin levels in both groups. In terms of postoperative problems, Fisher’s exact test revealed a significant difference between the two groups (P = 0.02).
Both draining techniques, when used prior to surgery, helped patients lower their bilirubin levels. However, the EBD approach was less harmful than the PTBD technique. In addition, a gastroenterologist served as the primary supervisor of the EBD procedure. Surgeons who specialize in surgery ought to be more closely supervised.
Reference: journals.lww.com/jfmpc/Fulltext/2022/12000/Comparing_the_efficacy_and_complications_of.26.aspx